{"nctId":"NCT00569192","briefTitle":"A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children","startDateStruct":{"date":"2007-12"},"conditions":["Asthma"],"count":360,"armGroups":[{"label":"0.25mg MAP0010","type":"EXPERIMENTAL","interventionNames":["Drug: 0.25mg MAP0010"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"0.135mg MAP0010","type":"EXPERIMENTAL","interventionNames":["Drug: 0.135mg MAP0010"]}],"interventions":[{"name":"0.135mg MAP0010","otherNames":[]},{"name":"0.25mg MAP0010","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female asthmatic children with mild to moderate persistent asthma.\n* 12 months to 8 years of age.\n* For children age 4 to 8 years: Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH (EPR-3) criteria.\n* For infants age 12 to \\<48 months old: 2 or more wheezing episodes in past 12 months which lasted \\> 1 day and affected sleep.\n* AND with at least one major or two minor risk factors.\n\nExclusion Criteria:\n\n* Any other significant childhood illness/abnormality or chronic lung disease\n* Any history of upper or lower respiratory tract infection, within 2 weeks of screening.\n* Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.\n* Use of any corticosteroid, including inhaled, parental, intranasal, or topical corticosteroid within 2 weeks of screening.\n* Any use of oral corticosteroids within 30 days of screening or prolonged use (\\>10 consecutive days) of oral corticosteroids, within 12 weeks of screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Daytime Composite Symptom Score","description":"The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nDaily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":"1.406"},{"groupId":"OG001","value":"2.96","spread":"1.329"},{"groupId":"OG002","value":"2.87","spread":"1.383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.38","spread":"1.722"},{"groupId":"OG001","value":"-1.77","spread":"1.618"},{"groupId":"OG002","value":"-1.56","spread":"1.591"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FEV1% Predicted","description":"The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.96","spread":"18.646"},{"groupId":"OG001","value":"91.20","spread":"17.713"},{"groupId":"OG002","value":"93.00","spread":"17.305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","spread":"13.068"},{"groupId":"OG001","value":"4.14","spread":"12.845"},{"groupId":"OG002","value":"0.36","spread":"16.657"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Nighttime Composite Symptom Score","description":"The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nNightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":"1.393"},{"groupId":"OG001","value":"2.97","spread":"1.466"},{"groupId":"OG002","value":"2.82","spread":"1.349"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"1.572"},{"groupId":"OG001","value":"-1.82","spread":"1.907"},{"groupId":"OG002","value":"-1.59","spread":"1.516"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PEF","description":"The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.94","spread":"49.343"},{"groupId":"OG001","value":"163.39","spread":"52.881"},{"groupId":"OG002","value":"165.34","spread":"49.133"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"44.544"},{"groupId":"OG001","value":"20.10","spread":"45.444"},{"groupId":"OG002","value":"15.02","spread":"45.306"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Daytime Individual Symptom Scores","description":"The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nIndividual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.544"},{"groupId":"OG001","value":"1.21","spread":"0.490"},{"groupId":"OG002","value":"1.18","spread":"0.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"0.734"},{"groupId":"OG001","value":"-0.68","spread":"0.705"},{"groupId":"OG002","value":"-0.58","spread":"0.664"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.591"},{"groupId":"OG001","value":"0.91","spread":"0.546"},{"groupId":"OG002","value":"0.88","spread":"0.550"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.615"},{"groupId":"OG001","value":"-0.58","spread":"0.563"},{"groupId":"OG002","value":"-0.49","spread":"0.589"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.557"},{"groupId":"OG001","value":"0.84","spread":"0.612"},{"groupId":"OG002","value":"0.81","spread":"0.602"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.635"},{"groupId":"OG001","value":"-0.51","spread":"0.632"},{"groupId":"OG002","value":"-0.49","spread":"0.626"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Nighttime Individual Symptom Scores","description":"The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nIndividual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.528"},{"groupId":"OG001","value":"1.20","spread":"0.495"},{"groupId":"OG002","value":"1.17","spread":"0.565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"0.663"},{"groupId":"OG001","value":"-0.69","spread":"0.720"},{"groupId":"OG002","value":"-0.61","spread":"0.638"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.563"},{"groupId":"OG001","value":"0.94","spread":"0.592"},{"groupId":"OG002","value":"0.90","spread":"0.548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.594"},{"groupId":"OG001","value":"-0.57","spread":"0.704"},{"groupId":"OG002","value":"-0.51","spread":"0.603"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"0.543"},{"groupId":"OG001","value":"0.83","spread":"0.622"},{"groupId":"OG002","value":"0.75","spread":"0.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.549"},{"groupId":"OG001","value":"-0.56","spread":"0.690"},{"groupId":"OG002","value":"-0.47","spread":"0.566"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":110},"commonTop":["Upper Respiratory Tract Infections","Asthma","Pyrexia","Nasopharyngitis"]}}}